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Purpose: This study aimed to compare clinically relevant outcomes following transarterial 
chemoembolization (TACE) and transarterial radioembolization (TARE) in patients with unre-
sectable hepatocellular carcinoma (HCC) using only prospective randomized clinical trials as 
a source of information.
Materials and methods: A meta-analysis was performed to compare the efficacy of TARE 
and TACE in treating patients with unresectable HCC. Only prospective randomized trials were 
included in the quantitative analysis. Overall and progression-free survival, disease control rate, 
and transplantation rate were the variables under analysis.
Results: Overall survival at 1 year was similar between the two treatment groups (OR =1.31, 
95% CI: 0.56–3.04, P=0.53). Progression-free survival at 1 year was also not statistically 
different between the two treatments (OR =0.23, 95% CI: 0.02–2.45, P=0.22). Although a higher 
proportion of patients underwent transplantation in the TARE group (30% vs 20.8%), this 
difference was not statistically significant (OR =0.68, 95% CI: 0.23–2.01; P=0.49).
Conclusion: TARE and TACE provide similar outcomes in unresectable HCC. The role of 
TARE should be explored in selected patient subpopulations in future clinical trials.
Keywords: selective internal radiation, SIRT, TARE, TACE, outcome, transplantation rates
Introduction
Transarterial chemoembolization (TACE) is the most widely used primary treatment 
for hepatocellular carcinoma (HCC).1 According to Western guidelines and clinical 
practice,2,3 as well as based on positive results from two randomized trials and three 
subsequent meta-analyses, it is the recommended first-line therapy for those patients 
who are in the intermediate stage and for those who are in the early stage but cannot 
be treated by resection, transplantation, or percutaneous ablation.4 Conventional TACE 
consists of the intra-arterial infusion of a cytotoxic agent usually mixed with the oily 
contrast medium Lipiodol, followed by embolization of the tumor blood vessels with 
gelfoam or calibrated particles, while in TACE based on drug-eluting beads (DEBs), 
ie, DEB-TACE, DEBs loaded with doxorubicin are used.5 Both procedures rely on 
the combined cytotoxic and ischemic effect to induce tumor cell killing.
In contrast, transarterial radioembolization (TARE, also called selective internal 
radiation therapy or SIRT) consists of the intra-arterial infusion of much smaller beads 
that are loaded with a radioactive isotope (yttrium-90), and it relies on the beta radia-
tion emitted by the isotope to induce tumor necrosis.5 In noncontrolled prospective 
and retrospective series, TARE resulted in high rates of objective tumor responses, 
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prolonged time to progression, and overall survival similar to 
those with TACE.5 Over the past few years, three prospective 
randomized clinical trials have compared both intra-arterial 
procedures with main end points other than overall survival.6,7 
However, survival outcomes have also been reported in these 
three trials. We have performed a meta-analysis to compare 
the efficacy of SIRT and TACE in treating patients with 
unresectable HCC considering only randomized studies that 
may provide the highest possible level of evidence.
Materials and methods
study design and inclusion criteria
Clinical trials comparing TACE and SIRT were searched in 
PubMed. Only randomized controlled trials that included 
patients with HCC were considered eligible and included in 
the quantitative analysis. A primary analysis was planned to 
compare overall survival between TACE and SIRT, while 
progression-free survival, disease control rate, progression 
rate, and rate of liver transplantation were secondary aims.
search strategy
Figure 1 reports the search strategy followed in this meta-anal-
ysis. A bibliographic research was conducted of the PubMed, 
Cochrane Library, and Embase databases. Keywords used 
included chemoembolization/TACE AND radioembolization/
TARE/SIRT/yttrium-90 AND hepatocellular carcinoma. 
Articles published in English until April 2017 were retrieved. 
Relevant reviews and meta-analyses of locoregional treat-
ments in unresectable HCC were also examined for potential 
suitable studies and data. The proceedings of the annual meet-
ings of the American Society of Clinical Oncology (ASCO 
and the ASCO gastrointestinal [ASCO GI] Cancers Sympo-
sium), European Society of Clinical Oncology (ESMO and 
ESMO GI), European Association for the Study of the Liver 
(EASL), American Association for the Study of Liver Dis-
eases (AASLD), and International Liver Cancer Association 
(ILCA) in the years 2010 through 2017 were systematically 
reviewed to detected unpublished data if pertinent.
Data extraction and management
Two authors (ACG and GLF) independently screened the 
titles and abstracts of all the selected studies. All the abstracts 
of potentially eligible trials were independently read by the 
same authors who decided whether the study was selected. 
The full text of all selected papers was then analyzed by the 
same authors to select all the trials finally included in the 
pooled analysis. When there are discrepancies in trial search 
or selection, they discussed with a third researcher (BS) to 
reach a final consensus. The internal validity of the trial was 
assessed by evaluating the method used for randomization, 
blindness, report of missing data, allocation sequence, and 
allocation concealment. All selected trials published as full-
text articles in a peer-reviewed journal were analyzed and 
classified using the Jadad score when possible. Qualitative 
and quantitative analyses of the selected articles were inde-
pendently performed by the same two authors (ACG and 
GLF); when there are discrepancies, they discussed with a 
third researcher (BS) to reach a final consensus. Overall and 
progression-free survival, disease control rate, and transplan-
tation rate were the variables under analysis.
statistical analysis
Meta-analysis was performed in accordance with the 
PRISMA statement recommendations.9 Data were entered 
in a computer database for transfer and statistical analysis 
in Review Manager 5.2. Heterogeneity among the trials was 
assessed with descriptive aim using the I2 test. I2 values above 
50% were deemed to suggest large among-trial heterogeneity, 
values of 25%–50% were deemed to show modest heteroge-
neity, and values below 25% were deemed to represent low 
heterogeneity. A level,5% was assumed to be statistically 
significant. Differences between categorical outcome param-
eters were quantified using the OR and corresponding 95% 
95% CI. Summary statistics for dichotomous outcome data 
were assessed using the Mantel–Haenszel method. Summary 
statistics for generic inverse variance data were calculated 
using the inverse variance method. Pooled analysis of the 
OR was performed using a random-effect model, assuming 
an error of 5% as an index of statistical significance.Figure 1 Process of selection of studies for the meta-analysis.
8 observational studies were
excluded
3 randomized trials
included in quantitative
analysis
317 articles were excluded
(118 reviews and 199 studies
did not meet eligibility criteria)
Electronic search:
–210 clinical studies
11 full-text articles
assessed for eligibility
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Results
study selection and characteristics
The combined search yielded 67 potentially relevant articles, 
64 of which were excluded because they were not random-
ized controlled trials. Three studies published from 2014 
to 2016 were analyzed. They included 49 HCC patients 
treated with TARE and 48 who underwent TACE. 6–8 One 
trial had time to progression as the primary end point and 
the preplanned sample size of 45 patients was not met due to 
slow recruitment.6 A second trial had health-related quality 
of life (HRQoL) as the primary end point and recruited the 
planned sample of 25 patients.7 The third trial was considered 
a pilot trial with no specific end point or sample size calcu-
lation and recruited 28 patients.8 The first two studies were 
judged to be of high quality and the last one was considered 
of moderate quality. Table 1 presents the characteristics of 
the patients in the three randomized clinical trials. Figure S1 
shows a funnel plot.
Outcomes
A significant heterogeneity between the trials was detected 
for progression-free survival (I 2 test: 76%), while no 
heterogeneity was detected for overall survival, dis-
ease control rate, or transplantation rate. As illustrated in 
Figure 2A, there were no differences in overall survival at 
1 year between the two treatment groups (OR =1.31, 95% 
CI: 0.56–3.04, P=0.53). Progression-free survival at 1 year 
was also not statistically different between the two treat-
ments (OR =0.23, 95% CI: 0.02–2.45, P=0.22), as shown 
in Figure 2B. Figure 3 shows how progression rates and 
disease control rates were also not significantly different 
between groups, with OR values of 0.61 (95% CI: 0.14–2.70, 
P=0.51) for progression rates and 1.80 (95% CI: 0.51–6.30, 
P=0.36) for disease control rates. Finally, although a higher 
proportion of patients underwent transplantation in the TARE 
group (30% vs 20.8%), such difference was not statistically 
significant (OR =0.68 95% CI: 0.23–2.01, P=0.49), as shown 
in Figure 4.
Discussion
TACE is recommended for patients with intermediate-stage 
HCC according to the Barcelona Clinic Liver Cancer (BCLC) 
classification,10 as well as for those with early-stage tumors 
that cannot be treated with percutaneous ablation, resection, 
or transplantation.1,2 This recommendation is based on strong 
scientific evidence coming from two randomized clinical 
trials in which carefully selected patients with low tumor 
burden were recruited.11,12 Without further scientific support, 
its use has nevertheless been expanded to treat almost any 
patient with liver-only or liver-predominant disease even 
in the presence of vascular invasion.13,14 In consequence, 
TACE is the most frequently used primary therapy for HCC 
worldwide.15
Table 1 Patient characteristics in the three randomized clinical trials
Trial SIRTACE6 Mainz7 PREMIERE8
Group TARE
n=13
TACE
n=15
TARE
n=12
TACE
n=12
TARE
n=24
TACE
n=21
age, years 65.8 66.7 71.8 70.5 62 64
Males, % 84.6 86.7 83.4 75 71 76
ecOg, n (%) 0
1
10 (76.9)
3 (23.1)
12 (80.0)
3 (20.0)
12 (100)
0 (0)
12 (100)
0 (0)
24 (100)
0 (0)
21 (100)
0 (0)
child–Pugh class, n (%) a
B
12 (92.3)
1 (7.7)
13 (86.6)
2 (13.4)
10 (83.3)
2 (16.7)
9 (75)
3 (25)
18 (75)
6 (25)
17 (81)
4 (19)
Bclc stage, n (%) a
B
c
5 (38.4)
5 (38.4)
3 (23.0)
4 (26.6)
8 (53.3)
3 (20.0)
13 (86.6)
2 (13.4)
0 (0)
10 (83.3)
2 (16.7)
0 (0)
18 (75)
6 (25)
0 (0)
17 (81)
4 (19)
0 (0)
Bilobar disease nD nD 8 (67) 7 (58) 7 (29) 7 (33)
Tumor size, mm nD nD 61.3 (36.4)a 60.8 (37.6)a 32 (27–37) 30 (23–36)
Tumor volume, ml 137.7 (237.6)a 235.6 (349.4)a nD nD nD nD
Total bilirubin (mg/dl) 1.00 (0.60)a 1.08 (0.45)a 1.17 (0.38–2.10) 1.26 (0.59–2.04) 1.3 (1.2–1.7) 0.9 (0.8–1.5)
albumin (g/l) 36.3 (3.9)a 42.0 (8.0)a 34.1 (28–43) 31.9 (24–39) 31 (27–33) 32 (29–34)
aFP (ng/ml) 636.0 (2,171.8)a 2,624.7 (9,525.3)a 14.0 (6.2–32,346) 7.8 (2.7–1,847) ,200: 88%
.200: 10%
,200: 90%
.200: 12%
Notes: aMean (sD). Values are expressed as median (iQr) unless otherwise indicated. Data from salem r et al; Pitton MB; Kolligs FT.6–8
Abbreviations: aFP, alpha-fetoprotein; Bclc, Barcelona clinic liver cancer; ecOg, eastern cooperative Oncology group; nD, not determined; Tace, transarterial 
chemoembolization; Tare, transarterial radioembolization.
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Figure 2 Forest plots of 1-year survival rate (A) and 1-year progression-free survival (B).
Abbreviations: Tace, transarterial chemoembolization; Tare, transarterial radioembolization.
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Figure 3 Forest plots of disease progression (A) and disease control rate (B).
Abbreviations: Tace, transarterial chemoembolization; Tare, transarterial radioembolization.
TARE was initially used to treat those patients who 
were considered suboptimal candidates for TACE due to 
the large tumor burden or vascular invasion.16,17 Contrary 
to TACE and due to the much smaller size of the beads, 
TARE can be safely used in patients with portal vein occlu-
sion or hepatofugal portal vein blood flow.18 For the same 
reason, it may also avoid the enhanced release of angiogenic 
factors, such as vascular endothelial growth factor (VEGF) 
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and others, caused by the hypoxic microenvironment induced 
by TACE. This increase in serum VEGF levels after TACE 
may indeed predict a worse overall survival in TACE-treated 
patients.19 Finally, permanent occlusion of the feeding vessels 
precludes subsequent TACE procedures and contraindicates 
the technique when the tumors cannot be targeted in a highly 
selective fashion.
Other indications of TARE have been integrated in 
experienced centers, including radiation lobectomy to rescue 
patients for resection and radiation segmentectomy to achieve 
complete tumor necrosis when percutaneous ablation is not 
feasible due to tumor location.20 The indications of TACE and 
TARE have thus progressively overlapped and TARE may in 
fact compete with TACE in some treatment characteristics. 
For instance, while the access of cytotoxic drugs to tumor 
cells is hampered by tumor volume constraints in TACE, 
leakage from Lipiodol, and physical distance of drug-eluting 
particles from target tumor cells, the delivery of radiation to 
tumor cells in TARE is secured provided the particles reach 
the tumors as confirmed in the pretreatment workup.
Retrospective studies comparing single-center experi-
ence and different meta-analyses have shown no differ-
ences in outcomes.21 However, a strong patient selection 
bias is inherent to such studies and, therefore, the quality 
of the information derived from these meta-analyses is low. 
This is the first meta-analysis comparing TACE and TARE 
that analyzes a significant number of patients derived only 
from prospective randomized clinical trials. The analysis 
indicates that overall and progression-free survival at 1 year, 
liver transplantation rate, and disease control rate were all not 
statistically different between the two therapeutic groups.
The PREMIERE trial6 demonstrated a benefit of TARE 
compared to TACE both in terms of time to progression 
(HR =0.122: 95% CI: 0.0227–0.557) and transplantation 
rate (54% vs 30%), which was not observed in the other two 
trials,7,8 where time to progression was similar and trans-
plantation in patients was done anecdotally. Indeed, median 
time to progression was not reached in the PREMIERE trial 
(progression rate at 1 year .90%) and it was 12.3 months in 
the Mainz trial, and progression-free survival was 3.6 months 
in the SIRTACE trial. These differences are probably due to 
the different patient characteristics. In the PREMIERE trial,6 
most patients (75%) were in the early stage and had unilobar 
involvement, while in the Mainz trial, most patients were in 
the intermediate stage and had bilobar tumor involvement; 
in the SIRTACE trial, a relevant 20% of patients were in 
the advanced stage due to altered performance status, which 
is usually associated with higher tumor burden and worse 
outcomes. The findings are therefore not surprising. TARE 
does not target micrometastases. It has already been reported 
that the more tumors at baseline, the higher is the chance of 
having early tumor progression;22 so time to progression is 
expected to be longer among patients at earlier stages and 
the impact of a highly active treatment on tumor progres-
sion is likely higher in this stage. What is less expected is 
that median time to new hepatic lesions was 7.3 months for 
TACE vs not reached for TARE in the PREMIERE trial.6 
A potential explanation is that identification of progression 
in the targeted liver volume could be more difficult in TARE-
treated livers due to the heterogeneous contrast enhancement 
produced by radiation in the nontumoral liver.
In terms of absolute cost, TARE is more expensive than 
TACE. However, no cost-effectiveness analysis has been 
reported so far. Such analysis should take into account the dif-
ferences in procedural cost, number of procedures (in TACE, 
80% of subjects receive multiple treatments,23 compared to 
93% of SIRT patients receiving single treatment),24 post-
procedural follow-up (less intensive for TARE), and benefit 
in terms of survival and HRQoL. The benefit in terms of 
HRQoL initially shown in a nonrandomized study10 was 
not confirmed in the randomized SIRTACE trial,8 reflecting 
the limitations of QoL evaluation. Additionally, in the 
various retrospective and prospective studies, as well as in 
meta-analyses, there was no difference in the occurrence of 
Odds ratio M–H,
random, 95% CITotal
15
12
24
48
TARE
12
12
Events
11
35
Study or
subgroup
Total (95% CI)
PREMIERE
Mainz
SIRTACE
Total events
Heterogeneity: τ 2=0.04; χ 2=2.06, df=2 (P=0.36); I 2=3%
Test for overall effect: Z=0.69 (P=0.49)
TACE
Events
13
11
14
38
Odds ratio M–H,
random, 95% CI
1.85 (0.15, 23.07)
3.26 (0.12, 88.35)
0.42 (0.13, 1.42)
0.68 (0.23, 2.01)
0.01 0.1
Favors TARE Favors TARE
1 10 100
Weight
(%)
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71.6
100
Total
13
49
12
24
Figure 4 Forest plots of transplantation rates.
Abbreviations: Tace, transarterial chemoembolization; Tare, transarterial radioembolization.
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adverse events between the two procedures, with a tendency 
to a lower toxicity of TARE.
The main limitations of this meta-analysis are that none 
of the randomized controlled trials had overall survival as the 
main end point and, consequently, the samples are small; this 
is reflected in the high heterogeneity of the studies. Moreover, 
the target populations were not homogeneous across trials, as 
previously mentioned. In addition, we must also consider that 
in both groups, the modalities and regimens are different.
Our meta-analysis reveals that TARE and TACE have 
similar effects in unresectable HCC patients in terms of 
overall survival, disease control rate, transplantation rate, 
and progression rate. It is very unlikely that further trials 
will be conducted in unrestricted HCC populations, and our 
results suggest that comparative trials could better focus on 
specific indications, including lobar portal vein invasion, 
downstaging, or reduction of the dropout rate from transplant 
waiting lists.
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Figure S1 Funnel plot of the study.
Notes: Funnel plot of progression free survival 1 year (A); overall survival 1 year (B); transplant rate (C); disease control rate (D); and progression disease (E).
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